2018
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts
Dougherty DH, Kwakkenbos L, Carrier ME, Salazar G, Assassi S, Baron M, Bartlett SJ, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mouthon L, Nielson WR, Poiraudeau S, Sauvé M, Boire G, Bruns A, Chung L, Denton C, Dunne JV, Fortin P, Frech T, Gill A, Gordon J, Herrick AL, Hinchcliff M, Hudson M, Johnson SR, Jones N, Kafaja S, Larché M, Manning J, Pope J, Spiera R, Steen V, Sutton E, Thorne C, Wilcox P, Thombs BD, Mayes MD, Albert A, Arsenault G, Bissonette L, Boutron I, Carreira P, Maia A, Dagenais P, Domsic R, El-Baalbaki G, Ells C, van den Ende C, Fligelstone K, Fortune C, Godard D, Gyger G, Harel D, Ikic A, Impens A, Jang Y, Artur Jose de B, Kennedy A, Khalidi N, Korman B, Leite C, Liang P, Marra C, Masetto A, Nielsen K, Portales A, Riggs R, Reyna T, Roux S, Schouffoer A, Steele R, Suarez-Almazor M, Varga J, Welling J, Wigley F, Wong-Rieger D, Cumin J, Delisle V, Fedoruk C, Fox R, Gholizadeh S, Jewett L, Levis B, Mills S, Pepin M, Persmann J, Turner K. The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology 2018, 57: 1623-1631. PMID: 29868924, DOI: 10.1093/rheumatology/key139.Peer-Reviewed Original ResearchConceptsIntervention Network CohortSPIN CohortSSc cohortAntibody frequencyCanadian Scleroderma Research Group cohortBaseline clinical featuresEuropean Scleroderma TrialsLarge SSc cohortPatient-reported outcome dataSSc renal crisisInterstitial lung diseasePatient-reported outcomesWeb-based cohortRenal crisisScleroderma cohortDcSSc patientsScleroderma TrialsOrgan involvementWhite patientsClinical featuresHigher proportionLung diseaseScleroderma patientsHigh prevalenceOutcome data
2016
Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis
Hinchcliff M, Whitfield M. Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis. 2016, 657-670. DOI: 10.1007/978-3-319-31407-5_49.Peer-Reviewed Original ResearchSystemic sclerosisPatient subsetsProgressive interstitial lung diseaseDiffuse cutaneous systemic sclerosisAppropriate patient subsetsScleroderma renal crisisCutaneous systemic sclerosisInvestigator-initiated trialPulmonary arterial hypertensionSubset of patientsDifferent patient subsetsInterstitial lung diseaseDifferent pathophysiological processesMolecular pathwaysPrecision medicineGene expression subsetsT lymphocyte activationUninvolved skin samplesInflammatory subsetRenal crisisSSc complicationsArterial hypertensionMycophenolate mofetilClinical improvementOrgan involvement
2015
Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report
Frech TM, Revelo MP, Ryan JJ, Shah AA, Gordon J, Domsic R, Hant F, Assassi S, Shanmugam VK, Hinchcliff M, Steen V, Khanna D, Bernstein EJ, Cox J, Luem N, Drakos S. Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. Journal Of Medical Case Reports 2015, 9: 136. PMID: 26055398, PMCID: PMC4469401, DOI: 10.1186/s13256-015-0587-7.Peer-Reviewed Original ResearchConceptsDiffuse systemic sclerosisSystemic sclerosisCardiac deathCase reportTissue metabolomicsEarly diffuse systemic sclerosisCardiac magnetic resonance imagingRight heart catheterizationPulmonary function testsCaucasian female patientSystemic sclerosis pathogenesisMagnetic resonance imagingRenal crisisHeart catheterizationCase presentationADigital ulcerationFemale patientsFunction testsSkin thickeningRare diseaseDisease pathogenesisHigh mortalityResonance imagingDyspneaSclerosis
2014
Antinuclear antibody-negative systemic sclerosis
Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD. Antinuclear antibody-negative systemic sclerosis. Seminars In Arthritis And Rheumatism 2014, 44: 680-686. PMID: 25578738, PMCID: PMC4447614, DOI: 10.1016/j.semarthrit.2014.11.006.Peer-Reviewed Original ResearchConceptsANA-negative groupANA-negative patientsPulmonary arterial hypertensionAntinuclear antibodiesSSc patientsDiffuse cutaneous involvementLower gastrointestinal involvementNegative antinuclear antibodyRight heart catheterizationScleroderma Family RegistrySSc-related antibodiesRodnan skin scoreSystemic sclerosis patientsANA-positive patientsRenal crisisVasculopathic manifestationsCause mortalityCutaneous involvementGastrointestinal involvementArterial hypertensionChart reviewClinical characteristicsHeart catheterizationMale patientsSkin score
2008
Systemic sclerosis/scleroderma: a treatable multisystem disease.
Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. American Family Physician 2008, 78: 961-8. PMID: 18953973.Peer-Reviewed Original ResearchConceptsInternal organ involvementSystemic sclerosisOrgan involvementRaynaud's phenomenonEndothelin-1 receptor blockerChronic connective tissue diseaseEnd-organ dysfunctionEnzyme inhibitor therapyHigh-dose corticosteroidsScleroderma renal crisisPulmonary arterial hypertensionPulmonary function testingConnective tissue diseaseDisease-modifying therapiesDistinct clinical subsetInternal organ dysfunctionOrgan-specific manifestationsPhosphodiesterase-5 inhibitorsMiddle-age womenOptimal patient careWidespread microvascular damageRenal crisisArterial hypertensionDigital ulcersLifestyle modification